UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 12, 2017

CV SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-54677**	**80-0944970**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2688 South Rainbow Boulevard, Suite B
Las Vegas, Nevada 89146
(Address of principal executive offices, Zip Code)

(866) 290-2157
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On September 12, 2017, CV Sciences, Inc. (the "Company") hosted a shareholder update conference call and provided shareholders highlights of the Company's latest updates and accomplishments during 2017 and strategic initiatives moving forward. The Company published materials in connection with the presentation, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference solely for purposes of this Item 7.01 disclosure.

The information set forth under this Item 7.01 of this Current Report on Form 8-K ("Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in this Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

99.1 CV Sciences, Inc. Corporate Update, dated September 12, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 13, 2017

CV SCIENCES, INC.

By: /s/ Michael Mona, Jr.
Michael Mona, Jr.
President and Chief Executive Officer

Exhibit 99.1


CV SCIENCES™
A LIFE SCIENCE COMPANY
CBD-BASED
PHARMACEUTICAL &
CONSUMER PRODUCTS
Corporate Update
September 12, 2017
Symbol: CVSI

SAFE HARBOR & DISCLAIMER

Safe Harbor:

This presentation may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties.

This Overview does not constitute an offer to sell or a solicitation of an offer to buy any securities of CV Sciences, Inc. The company is not soliciting any investment from this presentation or event attendees. Offers to sell or solicitations of offers to buy securities of the company will be made pursuant to the registration requirements of the Securities Act of 1933, or regulations of the Securities and Exchange Commission, and under relevant state securities laws; or in accordance with lawful exemptions from registration requirements under applicable federal and state securities laws and regulations.

CORPORATE OVERVIEW

CV Sciences, Inc.

- Primary operations in San Diego, CA
- Founded in 2012
- 48 employees
- Two operating divisions:
  1. Consumer products
  2. Drug development



CV SCIENCES™
A LIFE SCIENCE COMPANY

CONSUMER PRODUCTS DIVISION

CONSUMER PRODUCTS OVERVIEW

Overview

- 50+ SKUs
- Sales channels include:
  - 1300+ retail locations
  - 1000+ doctor offices
  - Strong wholesale presence
  - Growing ecommerce channel
- #1 Selling Hemp Products*
  #9 Company in the Natural Products Industry*

  **According to SPINS Scan Data*
- Strong branded products sales trend
- Category sales forecast - $452 million by 2020

CV SCIENCES™ A LIFE SCIENCE COMPANY

CONSUMER PRODUCTS

PlusCBD Oil™ - Branded Product

50+ SKUs

Raw Formulation

Total Plant Complex

Gold Formulation

CV SCIENCES™
A LIFE SCIENCE COMPANY

RETAIL STORE COUNT

CV SCIENCES™
A LIFE SCIENCE COMPANY

Q1 2017 - OPERATING RESULTS

	3 months ended March 31,		YoY Increase	
	2017	*2016*	*$*	*%*
Product sales	**$3,764,200**	**$2,422,700**	**$1,341,500**	**55%**
Gross margin	**2,433,000**	**1,625,600**	**807,400**	**50%**
Gross margin%	***64.6%***	***67.1%***		

CV SCIENCES™
A LIFE SCIENCE COMPANY

Q2 2017 - OPERATING RESULTS

	3 months ended June 30,		YoY Increase	
	2017	2016	$	%
Product sales	$4,081,800	$2,487,700	$1,594,100	64%
Gross margin	2,844,400	1,664,300	1,180,100	71%
Gross margin%	69.7%	66.9%		

CV SCIENCES™ A LIFE SCIENCE COMPANY

6 MONTHS ENDED JUNE 30, 2017 - OPERATING RESULTS

	6 months ended June 30,		YoY Increase	
	2017	2016	$	%
Product sales	$7,846,000	$4,910,400	$2,935,600	60%
Gross margin	5,277,400	3,289,900	1,987,500	60%
Gross margin%	67.3%	67.0%		

CV SCIENCES™
A LIFE SCIENCE COMPANY

SALES

CV SCIENCES™
A LIFE SCIENCE COMPANY

SPINS DATA *

Rank	Brand	Trailing 4 Weeks Sales
1	Nordic Naturals	$3,078,100
2	Barleans	$1,185,000
3	Natures Way	$850,100
4	Carlson	$826,200
5	Amazing Grass	$651,200
6	Private Label	$645,600
7	Now	$571,500
8	Spectrum Essentials	$542,800
9	PlusCBD Oil™	$515,800
10	Garden of Life	$511,800

* SPINS is the leading provider of analytics reporting for the Natural, Organic and Specialty Products Industry

CV SCIENCES™
A LIFE SCIENCE COMPANY

INDUSTRY GROWTH



Source: Hemp Business Journal estimates ($ in millions, consumer sales)

SYMBOL: CVSI

CV SCIENCES™
A LIFE SCIENCE COMPANY

DRUG DEVELOPMENT DIVISION

DRUG DEVELOPMENT PROGRAM

Overview

- **CVSI-007** – lead drug candidate
- **Cannabidiol** (CBD) and **nicotine** combination
- **Medical indication** – to support cessation of smokeless tobacco use and addiction
- **Proprietary technology** (patent pending)
- **Seeking 505(b)(2)** drug approval pathway

CV SCIENCES™
A LIFE SCIENCE COMPANY

MARKET POTENTIAL

No current FDA-approved drugs to treat smokeless tobacco use and addiction.

- There are only 2 smoking cessation FDA-approved drugs –Chantix (Pfizer) and Zyban (GSK)
- Until recently, both Chantix and Zyban had “black box warnings” that call attention to serious or life-threatening risks in taking these approved products.



CV SCIENCES™ A LIFE SCIENCE COMPANY

CURRENT FDA-APPROVED TREATMENTS

2015 REVENUE: $700 MILLION

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
See full prescribing information for complete boxed warning.

- **Serious neuropsychiatric events have been reported in patients taking CHANTIX. (5.1 and 6.2)**
- **Advise patients and caregivers that the patient should stop taking CHANTIX and contact a healthcare provider immediately if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior while taking CHANTIX or shortly after discontinuing CHANTIX. (5.1 and 6.2)**
- **Weigh the risks of CHANTIX against benefits of its use. CHANTIX has been demonstrated to increase the likelihood of abstinence from smoking for as long as one year compared to treatment with placebo. The health benefits of quitting smoking are immediate and substantial. (5.1 and 6.2)**

PRESCRIBING INFORMATION

ZYBAN®
(bupropion hydrochloride)
Sustained-Release Tablets

Suicidality and Antidepressant Drugs

Although ZYBAN is not indicated for treatment of depression, it contains the same active ingredient as the antidepressant medications WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL®. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of ZYBAN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. ZYBAN is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)

CV SCIENCES™
A LIFE SCIENCE COMPANY

UNMET MEDICAL NEED

Urgent Unmet Medical Need

- **Smokeless tobacco is carcinogenic** (risk of esophageal, oral and pancreatic cancers).
- **Smokeless tobacco is one of the most addictive and potent ways of consuming nicotine** (an average-size dip in the mouth for just 30 minutes can deliver as much nicotine as smoking three cigarettes).
- **Smokeless tobacco is strongly addictive** (equal to cocaine and heroin).
- Smokeless tobacco is an epidemic as recognized by the surgeon general.

There are currently NO FDA-approved drugs to support cessation of smokeless tobacco use and addiction.

CV SCIENCES™ A LIFE SCIENCE COMPANY

EPIDEMIC: SMOKELESS TOBACCO USE

Selected Epidemic Statistics

- **Serious impact on youth:** 5.8% of males 12-17 years of age reported use of smokeless tobacco.
- **47.2% of college baseball players still used smokeless tobacco**. NCAA rules eject both the player and manager for using smokeless tobacco during a game.
- **49% of all military personnel** used a tobacco product in the last 12 months.
- **12.8% of all military personnel** used smokeless tobacco in the last month.

CV SCIENCES™ A LIFE SCIENCE COMPANY

NICOTINE ADDICTION STATISTICS

- **1 billion** smokers worldwide
- **40 million** smokers in the U.S.
- **6 million deaths** worldwide from smoking, expected to increase to 8 million
- **300 million** smokeless tobacco users worldwide
- **9 million** smokeless tobacco users in the U.S.
- **250,000 deaths** worldwide and increasing from smokeless tobacco use

CV SCIENCES™
A LIFE SCIENCE COMPANY

TOBACCO USE TRENDS



Source: Euromonitor International, National Survey on Drug Use and Health Centers for Disease Control and Prevention

SYMBOL: CVSI

CV SCIENCES™
A LIFE SCIENCE COMPANY

NICOTINE ADDICTION STATISTICS (CONT)

Financial Impact

- **$300 Billion+ per year**
  Direct medical care and lost productivity

- **Depart of Defense reports $1.6 Billion per year** on tobacco-related care, increased hospitalization, and lost days ofwork.

Sources: CDC and *Tobacco Use and the Military*

CV SCIENCES™ A LIFE SCIENCE COMPANY

NICOTINE & CANNABIDIOL

Using patent-pending technology, CV Sciences' drug candidate (CVSI-007) combines cannabidiol (CBD) and nicotine to focus on a significant unmet medical need in treating smokeless tobacco use/addiction.

NICOTINE



+

CANNABIDIOL



CV SCIENCES™ A LIFE SCIENCE COMPANY

NICOTINE USE & ADDICTION

Overview

- **Physical Dependence**
  relaxant, stimulant, increased heart rate and blood pressure, decreased appetite
- **Emotional Dependence**
  "oral stimulation" of tobacco product used
- **Mental Dependence**
  nicotine is a mild "antidepressant"



CV SCIENCES™
A LIFE SCIENCE COMPANY

NICOTINE PK/PD - ANTIDEPRESSANT

Nicotine reaches the brain in 7-10 seconds

Nicotine is a mild antidepressant

- Mechanism of Action: monoamine oxidase ("MAO") inhibitor
- MAO is an enzyme that breaks down dopamine and other "feel good" neurotransmitters that produce pleasure and reward
- Lower levels of MAO result in higher dopamine levels

Nicotine half-life is approximately 1 hour

- Nicotine's PK/PD properties enhance its abuse potential with rapid distribution to the brain, drug levels peaking very quickly, and the acute effects dissipating quickly, requiring continued dosing.

CV SCIENCES™ A LIFE SCIENCE COMPANY

NICOTINE ADDICTION TREATMENT TYPICAL RELAPSE

No current FDA-approved drugs
(to treat smokeless tobacco use/addiction)

OTC Treatments –Nicotine Replacement Therapies (NRTs)



NRTs are the most widely used pharmacological product in treating nicotine addiction. Replacing cigarettes or smokeless tobacco products with another nicotine-only product, such as an NRT that is available OTC, has shown very high relapse rates.

Studies have shown up to **93%** of over-the-counter NRT users relapse and return to tobacco use within **6 months.**

CV SCIENCES™
A LIFE SCIENCE COMPANY

PROPRIETARY TECHNOLOGY

Internal PK/PD research on CBD contributed to our patent-pending technology



The **expanded therapeutic range** of combining nicotine and CBD, creates a product that effectively addresses all three nicotine addictions.

CV SCIENCES™ A LIFE SCIENCE COMPANY

BREAKING NICOTINE ADDICTION

Successfully treating nicotine addiction with nicotine/CBD combination therapy

CVSI-007 provides a therapeutic range that provides effective flexibility in treating the addiction rather simply replacing one nicotine product for another.

1. **Nicotine** –physical addiction (include nicotine)
2. **Oral Stimulation** –emotional addiction (oral format)
3. **Antidepressant** –mental addiction (≈ 10x MAO Inhibitor)

NICOTINE



CANNABIDIOL



CV SCIENCES™ A LIFE SCIENCE COMPANY

TARGET MARKET

Smokeless Tobacco Market

- Approximately **$5.3 billion** annual U.S. retail sales of smokeless tobacco products.
- Approximately **9 million** Americans use smokeless tobacco with enormous and growing worldwide use.
- **$2 billion** treatment market today, growing to **$4 billion** in 5-6 years.



CV SCIENCES™ A LIFE SCIENCE COMPANY

DRUG DEVELOPMENT TIMELINE

- Complete preclinical studies in early 2018
- Submit Investigational New Drug (IND) application in 2018
- Begin clinical trials in 2018

CV SCIENCES™
A LIFE SCIENCE COMPANY

ANNUAL MEETING FOLLOW UP

- July 2017 Annual Meeting in Las Vegas, NV
- Reverse Stock Split approved by shareholders
- No current plan to effectuate the reverse stock split for the balance of 2017

CV SCIENCES™
A LIFE SCIENCE COMPANY

SUMMARY POINTS

Consumer Product Segment

- Market leader
- Largest distribution network
- Strong sales growth in multiple channels
- Industry forecast - $452 million sales in 2020

Drug Development Segment

- No current FDA-approved drugs for smokeless tobacco use/addiction
- Smokeless tobacco treatment market is ≈ $2.0b, growing to $4b+
- Poor treatment options – NRTs & two "Black Box" warning drugs
- Proprietary technology (patent pending)
- Worldwide commercialization rights
- Anticipate clinical trials to commence in 2018

CV SCIENCES™
A LIFE SCIENCE COMPANY

CONTACT

CV Sciences, Inc.
Joseph Dowling, CFO
866-290-2157
joseph.dowling@cvsciences.com
cvsciences.com

Media & Investor Relations
IRTH Communications
Robert Haag, Managing Director
866-976-4754
CVSI@irthcommunications.com